Bulletin
Investor Alert

New York Markets Open in:

EyePoint Pharmaceuticals Inc.

NAS: EYPT

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Aug 15, 2022, 7:09 p.m.

/zigman2/quotes/210537129/composite

$

10.57

Change

-0.55 -4.95%

Volume

Volume 12,375

Quotes are delayed by 20 min

/zigman2/quotes/210537129/composite

Previous close

$ 11.11

$ 11.12

Change

+0.01 +0.09%

Day low

Day high

$10.59

$11.26

Open

52 week low

52 week high

$7.00

$21.50

Open

Annual Financials for EyePoint Pharmaceuticals Inc.

Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Sales/Revenue 7.54M5.86M20.37M34.44M36.94M
Cost of Goods Sold (COGS) incl. D&A 815,000-5.15M8.28M10.64M
COGS excluding D&A --2.54M5.64M7.87M
Depreciation & Amortization Expense 815,0002.65M2.6M2.65M2.77M
Depreciation 91,000194,000144,000189,000311,000
Amortization of Intangibles 724,0002.46M2.46M2.46M2.46M
Gross Income 6.72M-15.22M26.15M26.3M
20172018201920202021 5-year trend
SG&A Expense 24.83M52.32M63.08M63.44M81.58M
Research & Development 14.41M20.82M15.37M17.42M28.5M
Other SG&A 10.42M31.5M47.71M46.02M-
Other Operating Expense -----
Unusual Expense 472,00018.89M3.81M905,000(2.07M)
EBIT after Unusual Expense (18.58M)(68M)(51.67M)(38.2M)(53.21M)
Non Operating Income/Expense 91,000(18.89M)---
Non-Operating Interest Income -734,0001.05M58,000292,000
Equity in Affiliates (Pretax) -----
Interest Expense -3.28M6.18M7.26M5.5M
Gross Interest Expense -3.28M6.18M7.26M5.5M
Interest Capitalized -----
Pretax Income (18.49M)(89.44M)(56.79M)(45.39M)(58.42M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (18.49M)(89.44M)(56.79M)(45.39M)(58.42M)
Minority Interest Expense -----
Net Income (18.49M)(89.44M)(56.79M)(45.39M)(58.42M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (18.49M)(89.44M)(56.79M)(45.39M)(58.42M)
Preferred Dividends -----
Net Income Available to Common (18.49M)(89.44M)(56.79M)(45.39M)(58.42M)
EPS (Basic) (5.20)(10.50)(5.44)(3.54)(2.03)
Basic Shares Outstanding 3.53M8.51M10.43M12.84M28.76M
EPS (Diluted) (5.20)(10.50)(5.44)(3.54)(2.03)
Diluted Shares Outstanding 3.53M8.51M10.43M12.84M28.76M
EBITDA (17.29M)(46.47M)(45.26M)(34.64M)(52.51M)
Link to MarketWatch's Slice.